Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Skin Cancer
DermTech obtains melanoma testing coverage for additional 1.9 million people
The skin-based genomics test is a noninvasive way to enhance melanoma detection with a greater than 99% negative predictive value, DermTech said.
March 7, 2023
DermTech, Sonora Quest ink deal to broaden access to melanoma detection test
Under the agreement, Sonora Quest becomes the exclusive laboratory provider in Arizona for DermTech’s melanoma test.
November 16, 2022
Castle Biosciences reports results for gene expression tests in melanoma study
Castle Biosciences described studies evaluating its DecisionDx-Melanoma and DecisionDx-UM gene expression profile tests, conducted in collaboration with the National Cancer Institute.
October 27, 2022
Biocept expands commercial availability of CSF assay to metastatic melanoma
The new CNSide for melanoma assay uses an antibody cocktail optimized for the capture of melanoma cells based on unique cellular characteristics.
October 17, 2022
Tempus, Kartos Therapeutics collaborate on CDx for Merkel cell carcinoma treatment
The collaboration is aimed at developing a companion diagnostic (CDx) test to identify patients with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) who may be responsive to treatment with navtemadlin.
October 7, 2022
Castle Biosciences posts revenue surge, lower net loss in Q2
For the period (end-June 30), Castle had revenue of $34.8 million, up from $22.8 million in the second quarter of 2021. The firm delivered 11,034 total test reports in the second quarter, up 57% compared with the same period last year. Castle also pointed to a 44% increase in skin cancer gene expression report test volume.
August 8, 2022
Most Popular
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
FDA reissues EUA for Janssen COVID-19 vaccine, includes warning about risks of myocarditis, pericarditis
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Netherlands researchers combine CRISPR, bioluminescence in proof-of-concept infectious disease test
Werfen completes $2B acquisition of Immucor, expands presence in specialized diagnostics
Labcorp launches skin cancer assay
Studies have shown that LAG-3 is an immune-oncology target with demonstrable clinical benefit in patients with melanoma. Labcorp said its LAG-3 IHC method has demonstrated performance suitable for analysis of LAG-3 immune cell expression in clinical melanoma samples in a study published May 9 in the Journal of Clinical Pathology.
May 18, 2022
SkylineDx, Mayo Clinic evaluate genetic skin cancer test
The test can accurately predict the risk of regional metastasis at the time of melanoma diagnosis, according to SkylineDx.
September 25, 2019
Castle Biosciences moves ahead with skin cancer test
In a study of data drawn from patients at 18 centers, researchers identified a preliminary set of genes and developed a predictive algorithm associated with significantly higher risk for the recurrence of cSCC, a nonmelanoma type of skin cancer. The positive predictive value of the prognostic test was 60%, a result the company said compares well with current staging methods.
May 7, 2019
Page 1 of 1